Publication
Article
Pharmacy Times
The products include Loteprednol Etabonate Ophthalmic Suspension, Teriparatide Injection, Allopurinol Tablets, and Sitagliptin Tablets.
Loteprednol Etabonate Ophthalmic Suspension, 0.2%
From: Lupin
Compare to: Alrex
The FDA has given the green light to Lupin’s generic loteprednol etabonate ophthalmic suspension, 0.2%, a generic alternative to Bausch & Lomb’s Alrex. The suspension is indicated for temporary relief of the signs and symptoms of seasonal allergic conjunctivitis, including redness and itching in the eyes, watery discharge, and acute discomfort in bright sunlight. The conjunctiva may also become swollen and look purple, which can interfere with vision clarity. According to IQVIA data in October 2023, Alrex had a market value of approximately 29.1% million.
FOR MORE INFORMATION: lupin.com
Teriparatide Injection
From: Teva
Compare to: Forteo
Teva has launched teriparatide injection, a generic of Forteo. The injection is indicated to treat postmenopausal women who have osteoporosis and are at a heightened risk for fractures or who cannot tolerate other osteoporosis treatments. The injection can decrease the change of fractures in the spine and other bones. It is also indicated to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fractures, and for both men and women with osteoporosis as a result of glucocorticoid medicines, such as prednisone, for several months.
FOR MORE INFORMATION: tevapharm.com
Allopurinol Tablets, 100 mg and 300 mg
From: Lupin
Compare to: Zyloprim
Lupin has received FDA clearance for allopurinol tablets, 100 mg and 300 mg. The tablets are indicated for adults with signs and symptoms of primary or secondary gout, including acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy. Additionally, it is indicated for adult and pediatric patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anticancer therapies that cause elevated serum and urinary uric acid levels; and adults with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in men and 750 mg/day in women, despite lifestyle changes.
FOR MORE INFORMATION: lupin.com
Sitagliptin Tablets, 25 mg, 50 mg, and 100 mg
From: Lupin
Compare to: Januvia
Lupin’s generic sitagliptin tablets have been given FDA clearance in dosages 25 mg, 50 mg, and 100 mg. The tablets are indicated as an adjunct therapy to diet and exercise to improve glycemic control in patients with type 2 diabetes. As a dipeptidyl peptidase-4 inhibitor, sitagliptin helps manage blood sugar levels by increasing substances in the body that make the pancreas release more insulin and signals the liver to stop producing glucose when there is too much sugar in the blood.
FOR MORE INFORMATION: lupin.com
FDA Approves Ustekinumab-kfce as Sixth Biosimilar to Stelara